{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:29:46Z","timestamp":1765758586278,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Foundation for Applied Research in Gastrointestinal Oncology"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.suronc.2020.01.009","type":"journal-article","created":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T02:25:05Z","timestamp":1579919105000},"page":"96-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Unusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series"],"prefix":"10.1016","volume":"33","author":[{"given":"Paul H.","family":"Sugarbaker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. Anthony","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.suronc.2020.01.009_bib1","first-page":"311","article-title":"Malignant peritoneal mesothelioma: review of 25 patients","volume":"75","author":"Brenner","year":"1981","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.suronc.2020.01.009_bib2","series-title":"Peritoneal Carcinomatosis: Drugs and Diseases","first-page":"193","article-title":"Peritoneal mesothelioma: treatment approach based on natural history","author":"Averbach","year":"1996"},{"key":"10.1016\/j.suronc.2020.01.009_bib3","first-page":"40","article-title":"Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program","volume":"7","author":"J\u00e4nne","year":"2005","journal-title":"Clin. Lung Canc."},{"key":"10.1016\/j.suronc.2020.01.009_bib4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.lungcan.2008.08.013","article-title":"Malignant peritoneal mesothelioma: results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent","volume":"64","author":"Carteni","year":"2009","journal-title":"Lung Canc."},{"issue":"7","key":"10.1016\/j.suronc.2020.01.009_bib5","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.ejso.2017.01.009","article-title":"Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival","volume":"43","author":"Sugarbaker","year":"2017","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.suronc.2020.01.009_bib6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/cncr.20836","article-title":"Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy","volume":"15","author":"Yan","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.suronc.2020.01.009_bib7","series-title":"Cytoreductive Surgery & Perioperative Chemotherapy for Peritoneal Surface Malignancy. Textbook and Video Atlas","first-page":"17","article-title":"An overview of peritonectomy, visceral resection, and therapeutic laparoscopy for peritoneal surface malignancy","author":"Sugarbaker","year":"2017"},{"key":"10.1016\/j.suronc.2020.01.009_bib8","series-title":"Cytoreductive Surgery & Perioperative Chemotherapy for Peritoneal Surface Malignancy. Textbook and Video Atlas","first-page":"47","article-title":"Cancer chemotherapy for peritoneal metastases: pharmacology and treatment","author":"Van der Speeten","year":"2017"},{"issue":"1","key":"10.1016\/j.suronc.2020.01.009_bib9","first-page":"49","article-title":"Current methodologies for clinical assessment of patients with peritoneal carcinomatosis","volume":"15","author":"Jacquet","year":"1996","journal-title":"J. Exp. Clin. Canc. Res."},{"key":"10.1016\/j.suronc.2020.01.009_bib10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0378-4347(98)00566-0","article-title":"Rapid and sensitive determination of paclitaxel concentration in mouse plasma by high performance liquid chromatography","volume":"724","author":"Lee","year":"1999","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.suronc.2020.01.009_bib11","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","article-title":"Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastases: PHOENIX-GC Trial","volume":"36","author":"Ishigami","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.suronc.2020.01.009_bib12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.suronc.2020.01.009_bib13","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.suronc.2020.01.009_bib14","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a Gynecologic Oncology Group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.suronc.2020.01.009_bib15","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1055-3207(03)00045-0","article-title":"A review of peritoneal mesothelioma at the Washington Cancer Institute","volume":"12","author":"Sugarbaker","year":"2003","journal-title":"Surg. Oncol. Clin."},{"key":"10.1016\/j.suronc.2020.01.009_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1155\/2012\/752643","article-title":"Adjuvant bidirectional chemotherapy using an intraperitoneal port","volume":"2012","author":"Sugarbaker","year":"2012","journal-title":"Gastroenterol. Res. Pract."},{"issue":"10","key":"10.1016\/j.suronc.2020.01.009_bib17","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1200\/JOP.2016.011908","article-title":"Management of malignant peritoneal mesothelioma using cytoreductive surgery and perioperative chemotherapy","volume":"12","author":"Sugarbaker","year":"2016","journal-title":"J. Oncol. Pract."},{"key":"10.1016\/j.suronc.2020.01.009_bib18","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1245\/s10434-018-6631-2","article-title":"Impact of combination chemotherapy in peritoneal mesothelioma hyperthermic intraperitoneal chemotherapy (HIPEC): the RENAPE Study","volume":"25","author":"Malgras","year":"2018","journal-title":"Ann. Surg Oncol."}],"container-title":["Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096074041930533X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096074041930533X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T03:17:25Z","timestamp":1760757445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096074041930533X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":18,"alternative-id":["S096074041930533X"],"URL":"https:\/\/doi.org\/10.1016\/j.suronc.2020.01.009","relation":{},"ISSN":["0960-7404"],"issn-type":[{"type":"print","value":"0960-7404"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suronc.2020.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}